Pulmonx Corp. (LUNG)

Pulmonx Corp. stock has been impacted by several events in the past six months. The Q4 2025 earnings report showed an 8% increase in worldwide revenue for the full year but a 5% decrease in Q4 revenue. The company refinanced debt and implemented cost restructuring. The Q1 2026 earnings report showed a 9% decrease in worldwide revenue. Pulmonx refinanced its prior CIBC facility with a new $40.0 million senior secured term loan from Perceptive. Insiders have sold more company stock than they have bought. Pulmonx has a consensus "Hold" rating from brokerages. Pulmonx is scheduled to present at the Bank of America Securities 2026 Health Care Conference on May 12, 2026.

Pulmonx has experienced typical seasonal impacts on procedure volumes. The company anticipates continued growth in international markets and expects typical seasonal growth in pulmonary procedures in the U.S. in the fourth quarter.

Pulmonx Corporation is a commercial-stage medical technology company specializing in minimally invasive treatments for severe emphysema, a form of COPD. Its primary product is the Zephyr® Endobronchial Valve System, one-way valves delivered via a bronchoscopic procedure to collapse diseased portions of the lung. The Chartis® Pulmonary Assessment System assesses collateral ventilation to optimize Zephyr Valve treatment. The LungTraX™ Platform is a cloud-based CT analysis service that provides detailed reports to help identify target lobes for Zephyr Valve treatment.

Pulmonx Corporation is headquartered in Redwood City, California, and has an international presence with offices and distribution partners in Europe. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and other international regions, with the majority of its revenue generated from the USA.

Pulmonx Corporation is recognized as a global leader in minimally invasive treatments for COPD. Its Zephyr® Endobronchial Valve has received FDA pre-market approval as a "breakthrough device" and is included in global treatment guidelines. Over 100 scientific articles have been published on the clinical benefits of Zephyr Valves, validating its safety and efficacy.

Pulmonx Corp. has a mixed ownership structure. Approximately 91.04% of the stock is held by institutions, while 6.80% is held by insiders. Major institutional owners include PRIMECAP Management Company, Morgan Stanley, and BlackRock, Inc. Major individual owners include Theofanis Kolokotrones and Glendon E French III.